Chinook Therapeutics Management
Management criteria checks 3/4
Chinook Therapeutics' CEO is Eric Dobmeier, appointed in Apr 2019, has a tenure of 4.33 years. total yearly compensation is $4.84M, comprised of 12.4% salary and 87.6% bonuses, including company stock and options. directly owns 0.42% of the company’s shares, worth $12.16M. The average tenure of the management team and the board of directors is 2.2 years and 3.5 years respectively.
Key information
Eric Dobmeier
Chief executive officer
US$4.8m
Total compensation
| CEO salary percentage | 12.4% |
| CEO tenure | 4.3yrs |
| CEO ownership | 0.4% |
| Management average tenure | 2.2yrs |
| Board average tenure | 3.5yrs |
Recent management updates
Recent updates
Will Chinook Therapeutics (NASDAQ:KDNY) Spend Its Cash Wisely?
May 28
Companies Like Chinook Therapeutics (NASDAQ:KDNY) Are In A Position To Invest In Growth
Feb 14Chinook Therapeutics: Multiple Shots On Goal For IgAN
Aug 31Analysts Have Just Cut Their Chinook Therapeutics, Inc. (NASDAQ:KDNY) Revenue Estimates By 17%
Aug 12Chinook Therapeutics GAAP EPS of -$0.61 in-line, revenue of $0.42M in-line
Aug 08Chinook gets European orphan drug designation for BION-1301 for a type of kidney disease
Jul 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$246m |
| Mar 31 2023 | n/a | n/a | -US$216m |
| Dec 31 2022 | US$5m | US$601k | -US$188m |
| Sep 30 2022 | n/a | n/a | -US$118m |
| Jun 30 2022 | n/a | n/a | -US$92m |
| Mar 31 2022 | n/a | n/a | -US$97m |
| Dec 31 2021 | US$4m | US$547k | -US$103m |
| Sep 30 2021 | n/a | n/a | -US$160m |
| Jun 30 2021 | n/a | n/a | -US$149m |
| Mar 31 2021 | n/a | n/a | -US$114m |
| Dec 31 2020 | US$6m | US$438k | -US$82m |
Compensation vs Market: Eric's total compensation ($USD4.84M) is about average for companies of similar size in the US market ($USD6.59M).
Compensation vs Earnings: Eric's compensation has increased whilst the company is unprofitable.
CEO
Eric Dobmeier (54 yo)
4.3yrs
Tenure
US$4,841,699
Compensation
Mr. Eric L. Dobmeier, J.D., has been an Independent Director at Structure Therapeutics Inc. since December 2022. He is the President, Chief Executive Officer and Director of Chinook Therapeutics, Inc. sinc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.3yrs | US$4.84m | 0.42% $ 12.2m | |
| Chief Operating Officer | 2.2yrs | US$2.02m | 0.21% $ 6.1m | |
| Chief Scientific Officer | 2.2yrs | US$2.23m | 0.027% $ 773.8k | |
| Chief Financial Officer | 2.8yrs | no data | 0.054% $ 1.6m | |
| Senior Vice President of Finance & Accounting | less than a year | no data | no data | |
| Senior Vice President of Investor Relations & Corporate Communications | no data | no data | no data | |
| Senior VP & General Counsel | no data | no data | no data | |
| Senior Vice President of Human Resources | no data | no data | no data | |
| Executive Officer | 3.3yrs | US$2.41m | 0.011% $ 318.7k | |
| Senior Vice President of CMC & Technical Operations | 2.3yrs | no data | no data | |
| Senior Vice President of Product Development & Strategy | 1.6yrs | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data |
2.2yrs
Average Tenure
49yo
Average Age
Experienced Management: KDNY's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.3yrs | US$4.84m | 0.42% $ 12.2m | |
| Independent Director | 2.8yrs | US$233.60k | 0.0046% $ 133.4k | |
| Independent Director | 4.1yrs | US$227.60k | 0.0046% $ 133.4k | |
| Independent Director | 13.2yrs | US$233.10k | 0.033% $ 955.0k | |
| Independent Director | 1.4yrs | US$451.98k | 0.0018% $ 51.6k | |
| Independent Lead Director | 4.7yrs | US$244.60k | 0.62% $ 18.1m | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Independent Director | 2.8yrs | US$217.60k | 0.019% $ 537.1k |
3.5yrs
Average Tenure
54.5yo
Average Age
Experienced Board: KDNY's board of directors are considered experienced (3.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/08/12 02:27 |
| End of Day Share Price | 2023/08/10 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chinook Therapeutics, Inc. is covered by 11 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Antonia Borovina | Bloom Burton & Co. |
| Charles Duncan | Cantor Fitzgerald & Co. |
| Joshua Schimmer | Evercore ISI |